Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
Download App
简
繁
简
繁
EN
Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
HOME
·
02595.HK
GENFLEET-B (02595.HK): buyback reaches 2,907,800 H shares
Tags:
GENFLEET-B
02595.HK
Share Buyback
2026-11-09
GENFLEET-B (02595.HK): GFH276 Combo Trials Cleared in China and Australia
Tags:
GENFLEET-B
02595.HK
innovative drug
2026-11-04
GENFLEET-B (02595.HK): First Clinical Data for Pan-RAS Inhibitor GFH276 Selected as ESMO LBA
Tags:
NewTimeSpace
GENFLEET-B
02595.HK
2026-10-26
GENFLEET-B (02595.HK): Oral KRAS G12D Inhibitor Advances, 44% ORR in CRC Combo and 41% cORR in PDAC
Tags:
GENFLEET-B
02595.HK
innovative drug
2026-10-15
GENFLEET-B (02595.HK): GFH276 Data Selected as ESMO Late-Breaking Abstract
Tags:
GENFLEET-B
02595.HK
NewTimeSpace
2026-09-23
GENFLEET-B (02595.HK): GFH375 Combo Proposed for BTD in Colorectal Cancer
Tags:
GENFLEET-B
02595.HK
NewTimeSpace
2026-09-22
GENFLEET-B (02595.HK): Repurchases 872,000 H shares, about 0.227% of issued share capital
Tags:
GENFLEET-B
02595.HK
Share Repurchase
2026-09-21
GENFLEET-B (02595.HK): Phase II Data of GFH375 in Treated NSCLC Presented at WCLC, Confirmed ORR 52.1%
Tags:
NewTimeSpace
GENFLEET-B
02595.HK
2026-09-15
GenFleet Therapeutics (02595.HK): GFH375 Enters Phase‑II Study for First‑line NSCLC, Evaluating Monotherapy and Combination Regimens
Tags:
GenFleet Therapeutics
02595.HK
2026-08-26
GENFLEET-B (02595.HK): two first-in-class pancreatic cancer combination therapies of GFH375 advance to Phase II studies
Tags:
GENFLEET-B
02595.HK
Clinical Trial
2026-08-20
GENFLEET-B (02595.HK): Phase III study of world's first oral KRAS G12D inhibitor for NSCLC initiated; second registrational clinical study of GFH375 completes first patient enrolment
Tags:
GENFLEET-B
02595.HK
R&D Progress
2026-08-10
GENFLEET-B (02595.HK) plans to issue in total 13.6 million shares by placement, with estimated net proceeds of HKD 466.9 million
Tags:
GENFLEET-B
02595.HK
share placement
2026-07-15
GenFleet Therapeutics (02595.HK) Proposes Placing of 13.6 Million New H-shares at HK$34.69 Per Share
Tags:
GenFleet Therapeutics
02595.HK
2026-07-15
GENFLEET-B(02595.HK) closed 9.28% higher, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends
Tags:
GENFLEET-B
02595.HK
2026-04-24
NewTimeSpace | Breakthrough Designation for New Targeted Drug; GenFleet Therapeutics (02595.HK) Faces Commercialization Pressure Amid Heavy Book Losses
Tags:
02595.HK
GenFleet Therapeutics
NewTimeSpace
2026-04-10
Finance
METIS TECHBIO-P (07666.HK): plans H-share buyback of up to HKD 300m
Finance
HENGRUI PHARMA (01276.HK): hetrombopag NDA accepted in China
Research
HK Stock Connect Daily: NETEASE -17.60% on Gaming Slump - 20261120
Finance
WATER OASIS GP (01161.HK): FY profit seen doubling to HKD 165-175m
Research
HK AI Concept Stock Daily: BABA-W +3.48% Defies Slump - 20261120
Research
Hong Kong Recently Listed Stocks Daily Report: BRAINAURORA-B Rises 39.50% to Lead; Intelligent Driving and Smart Parking Gain Traction-20261120
Finance
NewTimeSpace | HK Close: HSI -1.89%, Semis and Hardware Lead Declines
Research
HK shares ETFs Daily Report: Fubon Taiwan Semiconductor ETF Falls 9.81% as CSI 300 and India Themes Rise-Nov 20, 2026
Research
Offshore Trust Insight | NIO-SW (09866.HK) -5.07%; Users Trust 50m
Research
HK Stock Connect Insight | RA MATERIALS (09607.HK) -13.26%; Stake Rise
Scan QR Code
Download App